share_log

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

XBiotech暫停風溼病項目,此前II期類風溼關節炎研究未能滿足主要終點,數據出現不規律;未來研究持有,待進一步分析結果。
Benzinga ·  12/23 09:03

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

XBiotech暫停風溼病項目,此前II期類風溼關節炎研究未能滿足主要終點,數據出現不規律;未來研究持有,待進一步分析結果。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論